Table 1.
Main laboratory tests at the time of delivery and thrombophilia screening 4 months later.
| Results | Reference range | |
|---|---|---|
| Blood count | ||
| Red cells (millions/mm3) | 4.27 | 4.30–5.70 |
| Hemoglobin (g/dl) | 12.4 | 12.0–17.5 |
| Hematocrit (%) | 39.4 | 35.0–50.0 |
| Total leukocytes (per mm3) | 17,500 | 3,500–10,500 |
| Neutrophils (%) | 83 | 50–70 |
| Lymphocytes (%) | 13 | 25–40 |
| Monocytes (5) | 4 | 8–13 |
| Platelets (per mm3) | 409,000 | 150,000–450,000 |
| Coagulation | ||
| D-dimer (ng/ml) | 17,216 | Up to 500 |
| Fibrinogen (mg/dl) | 353 | 200–393 |
| aPTT (s) | 35.8 | 29.0 |
| PT (s) | 9.8 | 12.3 |
| INR | 1.0 | 0.9–1.2 |
| Inflammatory biomarkers | ||
| CRP (mg/dl) | 0.90 | Up to 1 |
| ESR (mm/h) | 25 | Up to 10 |
| Ferritin (ng/ml) | 323.3 | 10–291 |
| Interleukin 6 (pg/ml) | 71.7 | <7 |
| Interleukin 1-beta (pg/ml) | 10.0 | <5 |
| Interleukin 10 (pg/ml) | 12.2 | <9.1 |
| TNF (pg/ml) | 10.1 | <8.1 |
| VEGF (pg/ml) | <31 | 31–86 |
| TGF-B (ng/ml) | 20.4 | 1.4–8.2 |
| Serology | ||
| Anti-SARS-CoV-2 IgG (S/C)a | 20.1 | <1.0 |
| Anti-SARS-CoV-2 Total (S/C)a | 115.0 | <1.0 |
| Anti-toxoplasmosis IgM (index)/IgG (UI/ml)b | <0.5/ <0.25 | <0.5/ <1.6 |
| Anti-rubella IgM (index)/IgG (UI/ml)c | <0.8/101.3 | <0.8/ <10.0 |
| Anti-CMV IgM/IgG (U/ml)c | <0.7/>500.0 | <0.7/ <0.5 |
| Anti-herpes simplex IgM/IgG (index)c | 0.5/30.0 | <0.9/ <0.9 |
| Anti-parvovirus B19 IgM/IgG (U/ml)d | <5.0/ <2.0 | <10.0/ <3.0 |
| Anti-ZIKV IgM/IgG | Neg/Pos | Neg/Neg |
| Anti-CHIKV IgM/IgG | Neg/Neg | Neg/Neg |
| Amniotic fluid | ||
| Leukocytes (per mm3) | 3,750 | <2 |
| Polymorphonuclear (%) | 6 | - |
| Mononuclear (%) | 94 | - |
| Red blood cells (per mm3) | 102,500 | <1,000 |
| Normal (%) | 95 | - |
| Crenated (%) | 5 | - |
| LDH (U/L) | 6,573 | <250 |
| Thrombophilia screening (four months after delivery) | ||
| Leiden Factor V G1691A mutation | Heterozygous | Not present |
| MTFHR C677T and A1298C mutations | Not present | Not present |
| FII G20210A mutation | Not present | Not present |
| CBS 844ins68 polymorphism | Not present | Not present |
| PAI-1 4G/5G polymorphism | 5G/5G Homozygous | 5G/5G Homozygous |
| Lupus anticoagulant antibody | 0.8 | ≤ 1.2 |
| Protein C (%) | 74 | 70–140 |
| Protein S (%) | 63 | 59–118 |
| Homocysteine (μmol/L) | 15.0 | <15 |
| IgA anti-cardiolipin antibodies (APL U/ml) | 1.6 | <14 |
| IgM anti-cardiolipin antibodies (MPL U/ml) | 0.9 | <10 |
| IgA anti-β2glycoprotein I antibodies (U/ml) | 6.2 | <7 |
| Antithrombin III activity (%) | 99.9 | 79.4–112 |
| PAI-1 gene mutation | Negative (5G/5G) | (5G/5G) |
aPTT, activated partial thromboplastin time; PT, prothrombin time, INR, international normalized ratio; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; TGF-B, transforming growth factor beta; SARS-CoV-2, severe acute respiratory syndrome caused by the coronavirus type 2; CMV, cytomegalovirus; ZIKV, Zika virus; CHIKV, chikungunya virus; LDH, lactic dehydrogenase; PAI-1, plasminogen activator inhibitor 1; MTFHR, methylene-tetrahydrofolate reductase; CBS, cystathionine β-synthase.
Immunochemoluminescence.
CMIA, chemiluminescent microparticle immunoassay.
CLIA, chemiluminescent immunoassay.
ELISA, enzyme-linked immunosorbent assay.